Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2019-11-18 Director's Dealing
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Powiadomienia o transakcjach na instrumentach finansowych Mabion S.A. dokonanych przez osobę pełniącą obowiązki zarządcze - Content (EN)
Director's Dealing Classification · 98% confidence The document text explicitly states that notifications regarding transactions carried out by a person discharging managerial responsibilities (a director/executive) were received and are attached. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for this is DIRS.
2019-11-18 English
Powiadomienia o transakcjach na instrumentach finansowych Mabion S.A. dokonanych przez osobę pełniącą obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (329 characters) and reports that the Management Board (Zarząd) received notifications on 18.11.2019 from a person holding a management position (Sławomir Jaros, Member of the Management Board) regarding transactions made on the company's financial instruments. This directly describes insider trading activity by a director/executive. This aligns perfectly with the definition of Director's Dealing (DIRS). The text also mentions that the content of the notifications is attached to the report, but the core subject is the director's transaction, making DIRS the primary classification over RPA/RNS.
2019-11-18 Polish
Mabion_Pozostale_Informacje_do_Raportu Kwartalnego_Q3_2019
Management Reports Classification · 99% confidence The document is explicitly titled "Pozostałe informacje do raportu kwartalnego Mabion S.A. za III kwartał 2019 roku" (Other information for the quarterly report of Mabion S.A. for the third quarter of 2019). It contains detailed financial data (Selected financial data, balance sheet items, income statement items) covering the first nine months of 2019, management structure information, and shareholder structure. This content structure is characteristic of a comprehensive periodic financial report covering an interim period (not annual). Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report (RPA) because it contains the substantive financial data and narrative sections.
2019-11-14 Polish
Mabion MSSF 2019 Q3
Interim / Quarterly Report Classification · 100% confidence The document is a 'Śródroczne Skrócone Sprawozdanie Finansowe' (Interim Condensed Financial Statement) for Mabion S.A. for the 3 and 9-month periods ending September 30, 2019. It contains detailed financial statements, including the Statement of Comprehensive Income, Statement of Financial Position, and Statement of Cash Flows. As it provides substantive financial data for an interim period, it is classified as an Interim/Quarterly Report. 9M 2019
2019-11-14 Polish
Złożenie odpowiedzi w ramach drugiego wniosku rejestracyjnego Spółki dotyczącego leku MabionCD20 w Europejskiej Agencji Leków - Content (PL)
Legal Proceedings Report Classification · 95% confidence The document text is very short (1211 characters) and discusses the submission of responses to the European Medicines Agency (EMA) regarding the registration procedure for a drug (MabionCD20). It details the status of a regulatory submission process, specifically mentioning the continuation of the assessment by the agency and the expectation of an opinion from the CHMP. This content relates to ongoing regulatory or legal matters concerning product approval, rather than being a full financial report (like 10-K or IR) or a general announcement of a report release (RPA). Given the focus on legal/regulatory proceedings involving an external body (EMA/CHMP), the most appropriate category is Legal Proceedings Report (LTR), as it concerns significant regulatory actions affecting the company's product pipeline. It is not a standard earnings release (ER) or a general regulatory filing (RNS) because it is highly specific to a drug registration status update.
2019-11-12 Polish
Złożenie odpowiedzi na drugą rundę pytań w procedurze rejestracyjnej leku MabionCD20 w Europejskiej Agencji Leków - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (921 characters) and refers to a previous report (raport bieżący nr 20/2019) regarding an application process with the European Medicines Agency (EMA) for a drug (MabionCD20). The core message is an update that responses to the second round of questions have been successfully submitted to the EMA system, allowing the evaluation to continue. This is a specific, non-financial, regulatory/procedural update concerning a product application status. It does not fit the definitions for 10-K, ER, IR, or CT. Since it is a specific regulatory update that doesn't fit the more precise categories (like DIRS, DIV, MANG), the most appropriate general category for miscellaneous regulatory announcements is 'Regulatory Filings' (RNS). It is not an announcement of a report publication (RPA) but a status update on a regulatory procedure.
2019-11-11 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.